Resource Summary Report

Generated by RRID on Aug 4, 2026

p44/42 MAP kinase (phosphorylated Erk1/2)

RRID:AB_331646
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9101, RRID:AB_331646

Antibody Information

URL: http://antibodyregistry.org/AB_331646

Proper Citation: Cell Signaling Technology Cat# 9101, RRID:AB_331646

Target Antigen: Erk1/2

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP, IF-IC, F
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE
Consolidation: AB_2315036, AB_2315114, AB_2315111, AB_2315113, AB_331647

Antibody Name: p44/42 MAP kinase (phosphorylated Erk1/2)

Description: This polyclonal targets Erk1/2

Target Organism: Human, D.melanogaster, Bovine, Rat, Monkey, Zebrafish, C.elegans, Pig, Mouse, Mink, Hamster

Defining Citation: PMID:19937707, PMID:18196540, PMID:18459137

Antibody ID: AB_331646

Vendor: Cell Signaling Technology

Catalog Number: 9101

Alternative Catalog Numbers: 9101S, 9101L

Record Creation Time: 20250820T023650+0000

Record Last Update: 20250820T140318+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development

No alerts have been found for p44/42 MAP kinase (phosphorylated Erk1/2).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 740 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Ma Y, et al. (2026) Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degraders. Cell reports, 45(1), 116784.

Diamond EL, et al. (2026) RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition. Cancer cell, 44(1), 203.

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. Cancer discovery, 16(1), 81.

Kong CH, et al. (2026) Sinapic acid balances the excitatory and inhibitory neurotransmitter systems to mitigate post-traumatic stress disorder-like behaviors. Life sciences, 388, 124201.

Jasani N, et al. (2025) PHGDH Induction by MAPK Is Essential for Melanoma Formation and Creates an Actionable Metabolic Vulnerability. Cancer research, 85(2), 314.

Queen NJ, et al. (2025) Environmental Enrichment Normalizes Metabolic Function in the Murine Model of Prader-Willi Syndrome Magel2-Null Mice. Endocrinology, 166(3).

Kang M, et al. (2025) Cd99l2 regulates excitatory synapse development and restrains immediate-early gene activation. Cell reports, 44(1), 115155.

Hundsdorfer L, et al. (2025) ERK activation waves coordinate mechanical cell competition leading to collective elimination via extrusion of bacterially infected cells. Cell reports,

44(1), 115193.

Lan Z, et al. (2025) ATP8A1-translocated endosomal phosphatidylserine fine-tunes the multivesicular body formation and the endo-lysosomal traffic. iScience, 28(3), 111973.

Watanabe K, et al. (2025) Maternal progesterone and adipose mPR? in pregnancy regulate the embryonic nutritional state. Cell reports, 44(3), 115433.

Lende-Dorn BA, et al. (2025) Chemogenetic tuning reveals optimal MAPK signaling for cell-fate programming. Cell reports, 44(9), 116226.

Anastasaki C, et al. (2025) Aberrant coupling of glutamate and tyrosine kinase receptors enables neuronal control of brain-tumor growth. Neuron.

Díaz NM, et al. (2025) Opsin 5 mediates violet light-accelerated wound healing in mammalian corneas. Cell reports, 44(8), 116045.

Wyatt RA, et al. (2025) A calcium-sensing receptor dileucine motif directs internalization to spatially distinct endosomal signaling pathways. iScience, 28(6), 112651.

Pan L, et al. (2025) The gut-brain axis mechanism of normal appetite induced by kynurenic acid. Cell reports, 44(5), 115659.

Lamichhane A, et al. (2025) Targeting CAFs-Mediated Stromal Signaling in a Patient-Derived Organotypic Colorectal Tumor Model. Molecular cancer therapeutics, 24(8), 1265.

Pagliarini RA, et al. (2025) STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(14), 3002.

Chen Y, et al. (2025) Lung adenocarcinoma surfaceome remodeling with EGFR inhibitors uncovers placental alkaline phosphatase as a target for combination therapy. Cell reports. Medicine, 6(12), 102513.

Ducourneau EG, et al. (2025) Obesogenic diet impairs memory consolidation via the hippocampal endocannabinoid system. Current biology : CB, 35(23), 5820.

Ouellette JM, et al. (2025) Altered sphingolipid profile in response to skeletal muscle injury in a mouse model of type 1 diabetes mellitus. American journal of physiology. Cell physiology, 328(1), C273.